Mid and South Essex NHS Foundation Trust - Broomfield Hospital

The Mid and South Essex NHS Foundation Trust - Broomfield Hospital incorporates Chelmsford & Essex Hospital and Broomfield Hospital https://www.mse.nhs.uk/
Chemotherapy toxicity data presented at trust level because 86% of data was coded at trust level.

View Trust Services

This trust offers the following services:

  • Diagnostic and pre-operative services:
    • On-site PET-CT facilities
    • On-site Cardio-Pulmonary Exercise Testing (CPET) facilities
    • Routine Genetic Testing for Lynch Syndrome
  • Surgical services:
    • On-site hepatobiliary surgical team
    • Robotic surgery
  • Advanced disease services:
    • Dedicated Specialist Advanced Nurse
    • Dedicated Specialist Advanced MDT
    • Dedicated Specialist Advanced Outpatient Clinic
    • Distal sacrectomy
    • Extended lymphadenectomy
  • Support service facilities:
    • Dedicated nurses for ERAS services
    • Availability of 24 hour palliative care advice
    • 7-day access to face-to-face palliative care services
    • On-site psychology services

Data Quality
All Patients: Trust Network National
Number of patients in Audit 259 1867 35779
Case ascertainment (%) Good Good Good
Data completeness of:
– Pre-treatment TNM (%) 51 85 86
– Performance status (%) 100 96 89
Patients having major resection: Trust Network National
Number of patients in Audit 158 1016 19631
ASA grade 1 (%) 18 11 9
ASA grade 2 (%) 56 50 53
ASA grade 3 (%) 25 36 31
ASA grade 4+ (%) N/A 3 2
ASA grade not recorded (%) N/A 1 4
Data completeness of:
7 Audit items for risk-adjustment (%) 100 93 87

Key:

> 80%
50 - 80%
< 50%

Management of all patients
All Patients: Trust Network National
Number of patients in Audit 259 1867 35779
Seen by Clinical Nurse Specialist (%) 99 94 88

Management of patients having major resection
Patients having major resection: Trust Network National
Number of patients in Audit 158 1016 19614
Distant metastases (%) 6 5 5
Urgent or emergency surgery (%) 13 11 15
At least 12 lymph nodes excised (%) 92 89 84
Laparoscopic surgery attempted (%) 78 80 72
Risk-adjusted length of stay > 5 days (%) 43 46 55
Patients having major resection for stage III colon cancer: Trust Network National
Number of patients in audit 15 N/A 10747
Adjuvant chemotherapy (%) 80 N/A 62
Patients receiving chemotherapy after major resection for stage III colon cancer: Trust Network National
Number of patients in audit 95 N/A 6608
Severe acute toxicity after adjuvant chemotherapy (%) 30 N/A 22

Rectal cancer patients
Patients having major resection: Trust Network National
Number of patients in Audit 29 N/A 4251
Neoadjuvant therapy (%) 19 N/A 33
Circumferential resection margin: Recorded (%) 100 94 89
Circumferential resection margin: Negative (%) 93 90 83
Rectal volume 25 N/A 4377
Patients in APER/Hartmanns estimate: Trust Network National
Number of patients in APER/Hartmanns estimate 22 936 19644
APER/Hartmanns (%) 14 34 37

Compare trust outcomes

Copyright © 2024 National Bowel Cancer Audit | Lovingly Crafted by Mixd